Kala Bio (KALA)SEE REMARKS sold ~$39K

~$39K

Approx. value · 47K sh @ $0.83

36K

Holds after · shares reported

Traded

Oct 22, 2025

Filed

Oct 25, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 28, 2025Company filing · Form 8-K · Restructuring, Other newsAnnounced job cuts, closures or a restructuring, and reported other company news“On September 28, 2025, the board of directors (the “Board”) of KALA BIO, Inc. (the “Company”) determined to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to take steps to preserve cash as the Company explores its strategic options.”
2. Sep 28, 2025Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member“On October 2, 2025, the Company entered into retention agreements (each, a “Retention Agreement”) with Todd Bazemore, the Company’s President and Chief Executive Officer, Mary Reumuth, the Company’s Chief Financial Officer, and Kim Brazzell, Ph.D., the Company’s Head of Research and Development and Chief Medical Officer.”
3. Sep 29, 2025Company filing · Form 8-K · Debt acceleratedHad a debt or obligation accelerated“On September 29, 2025, KALA BIO, Inc. (the “Company”) received a written notice (the “Notice”) of event of default from Oxford Finance LLC (“Oxford”) with respect to that certain Loan and Security Agreement, dated as of May 4, 2021 (as amended, the “Loan Agreement”), by and among the Company, Combangio, Inc. and Oxford, as lender and collateral agent.”
4. Oct 19, 2025Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“On October 19, 2025, in connection with the Reduction, the Board terminated without cause the employment of Todd Bazemore, the Company’s President and Chief Executive Officer, effective immediately.”
5. Oct 22, 2025 · this disclosureInsiderOfficer sold ~$39K of KALA shares in the open market

What came next

1. Oct 22, 2025Insider · 3 peopleInsiders: 3 sales (~$84K)
2. Oct 23, 2025Insider · 2 peopleInsiders: 2 sales (~$126K)
3. Nov 9, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
4. Nov 10, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On November 10, 2025, KALA BIO, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”) for continued listing on The Nasdaq Capital Market, as the market value of the Company’s…”
5. Nov 20, 2025Company filing · Form 8-K · Material agreement, Agreement endedChanged a top executive or board member, and signed an important agreement (and 4 more items)“On November 21, 2025, the Board terminated without cause the employment of Mary Reumuth, the Company’s Chief Financial Officer and Secretary, effective as of the business day following the First Closing.”
6. Dec 4, 2025Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
7. Dec 15, 2025Company filing · Form 8-K · Auditor changeChanged its auditor“On December 15, 2025, the Audit Committee of the Board of Directors of KALA BIO, Inc. (the “Company”) approved the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective as of December 15, 2025.”
8. Dec 19, 2025Company filing · Form 8-K · Auditor change, Executive changeChanged its auditor, and changed a top executive or board member“As disclosed in the Company’s Preliminary Proxy Statement for its 2025 annual meeting (the “2025 Annual Meeting”) as filed on December 19, 2025, each of Marjan Farid, M.D., Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen tendered on December 19, 2025 a conditional resignation from their positions as director effective immediately after the Company’s 2025 Annual Meeting if stockholder…”
9. Dec 30, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
10. Jan 8, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
11. Jan 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On January 20, 2026, KALA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between December 3, 2025, to January 16, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq…”
12. Jan 30, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesControl of the company changed hands, and changed a top executive or board member (and 4 more items)“Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.”
13. Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, David Lazar tendered his resignation to the Board of the Directors (the “ Board ”) as the Chief Executive Officer and Chief Financial Officer of KALA BIO, Inc. (the “ Company ”), effective as of the same date.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Kala Bio

OQRO holds no insider, Congress, fund or contract record for Kala Bio dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KALA page.

Other recent filings by Romulus K Brazzell, SEE REMARKS

• SEC Form 4 at Kala Bio (KALA)Jun 27, 2025
• SEC Form 4 at Kala Bio (KALA)Jun 5, 2025
• SEC Form 4 at Kala Bio (KALA)Jan 8, 2025

The full history of Romulus K Brazzell, SEE REMARKS is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Kala Bio

• SEC Form 4Oct 25, 2025
• SEC Form 4Oct 25, 2025
• SEC Form 4Oct 25, 2025
• SEC Form 4Oct 25, 2025
• SEC Form 4Oct 25, 2025
• SEC Form 4Jun 27, 2025

Everything OQRO holds on this company is on its KALA page.